| O
|
| Drug |
CYP interaction |
Clinical consequences |
| olanzapine : does NOT inhibit 1A2 [Pharmacotherapy 1998 Nov-Dec;18(6):1237-48]
or indeed other CYPs.
| 1A2 : some metabolism
(minor = 2D6)
| Potential for interaction with 1A2 inhibitors
(fluvoxamine), and inducers
(smoking,
? carbamazepine).
|
| omeprazole (proton pump inhibitor)
'few significant interactions'
| CYP2C19 : metabolism
(? also 2C8, 2C18)
| benefit of low activity : increased peptic ulcer cure!
|
| CYP1A2
| ? INDUCES (inhibition of 1A2 activity also occurs, but
is clinically irrelevant)
|
| 2C19 : INHIBITS (IC50 ~ 3 to 10 µmol)
| potential for interactions
e.g. with diazepam(?).
|
| ondansetron
| CYP1A2 (substrate), even 1A1
| ?
|
| 2D6 : metabolism
| ?
|
| 3A4 : METABOLISM
| rifampicin lowers ondansetron area under concentration curve by 50 to 60%
|
| 2E1 : metabolism
| ?
|
| Opioids - SEE ALSO INDIVIDUAL AGENTS.
| CYP3A4 : hi activity
| less effective
|
| CYP3A4 : low activity
| delayed clearance
|
| oral contraceptives (see also components)
| CYP3A4 : hi activity
| ineffective
|
| CYP2C19
| INHIBIT
|
| orphenadrine
| 2B6 : INHIBITS (NOT selective: [Drug Metab Dispos 1997 Mar;25(3):390-3] )
| interaction with eg tricyclic antidepressants
|
| 2D6 : inhibits
| ?
|
| 2C9 : (inhibits)
| ?
|
| oestradiol : See estradiol
|
| oxcarbazepine (anticonvulsant)
| 3A4 : INDUCED
| significant interaction with eg oral contraceptives
|
| oxycodone
| 2D6 : activated to oxymorphone
| blocking 2D6 blocks activation.
|